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Background: There are many reports of cognitive dysfunction in patients receiving chemotherapy or targeted
therapies. Many antineoplastic agents may be involved in the condition also known as “chemo brain” or “chemo fog”.
Case presentation: Two male patients (aged 41 and 70) with multiple myeloma developed severe, rapidly progressing
cognitive impairment (mostly involving episodic memory) and loss of independence in activities of daily living during
lenalidomide-based treatment. On withdrawal of the drug, one patient recovered normal cognitive function and
independence in activities of daily living, whereas mild cognitive impairment persisted in the other patient. The
Naranjo Adverse Drug Reaction Probability Scale score was 6 out of 13 for the first patient and 5 out of 13 for the
second, suggesting a probable causal relationship between the adverse event and lenalidomide administration.
Conclusion: Lenalidomide may induce particular cognitive disorders (notably episodic memory impairments) in some
patients. The drug’s putative neurotoxicity is probably promoted by specific risk factors (such as previous
chemotherapy, prior mild cognitive impairment, age and the presence of cerebrovascular lesions).
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Several studies have suggested that both malignant tumors
and their treatments (such as chemotherapy, targeted
therapy and radiotherapy) may induce cognitive impairment
[1-4]. Indeed, the terms “chemo brain” and “chemo fog”
are often used to describe cognitive impairment observed
before, during or after chemotherapy or systemic adminis-
tration of other antineoplastic agents. Disabling cognitive
disorders may affect between 15% and 50% of patients
undergoing chemotherapy [5]. However, literature reports
diverge as to the types and durations of cognitive impair-
ments observed during chemotherapy. In most cases,
the manifestations of chemo brain are mild but may have
a slight impact on activities of daily living (ADL). The
most common reported symptoms are fatigue, feelings
of confusion or mental fogginess, inability to focus or
concentrate, decreased attention span, slower thinking
and impairments in remembering details, handling multiple* Correspondence: adeline.rollin@chru-lille.fr
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distribution, and reproduction in any mediumtasks or learning new skills. Although a range of cognitive
adverse effects have been observed during chemotherapy,
impairments in memory, processing speed and executive
function appear to be the most frequently reported
[6,7]. The duration of the symptoms varies and long-term
cognitive impairment has been observed [5]. Although most
of the studies in this field concern cognitive complaints in
women receiving adjuvant chemotherapy for breast cancer,
cognitive complaints can occur in many cancer settings.
Atrophy in some brain areas on magnetic resonance
imaging (MRI) may be correlated with attention or visual
memory performances [8,9].
Preliminary studies have suggested the existence of
host-related risk factors (e.g. age, genetic polymorphisms,
immune reactivity, nutritional factors, hormone profile
and the lack of cognitive reserve) and disease-related
factors (e.g. tumor gene mutations, the induction of
pro-inflammatory cytokines and paraneoplastic disorders)
that contribute to cognitive decline [10-12]. Little is known
about the mechanism(s) of chemo brain, although several
hypotheses have been put forward: direct neurotoxic
effects, oxidative stress and DNA damage, induced hormonal
changes, immune dysregulation, cytokine release, vascularntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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predisposition [11,12]. There are number of guidelines
and consensus statements on the assessment of cognitive
function in chemotherapy trials [5,12-14].
Here, we report on two multiple myeloma (MM) patients
who presented with memory impairments and reduced
independence in ADL during treatment with lenalidomide.
Case presentations
Patient 1
The patient was a 41-year-old male with a history of arterial
hypertension and aortic dissection. Two years previously,
the patient had presented with an International Staging
System (ISS) grade III immunoglobulin (Ig) G lambda MM.
There was no chromosome 17 deletion or 4;14 transloca-
tion. The MM was initially treated with a three-month
course of bortezomib and dexamethasone (as part of the
induction phase with a view to possible transplantation)
but merely stabilized. The patient then received vincristine/
adriamycin/dexamethasone (VAD) as a salvage induction
regimen that was subsequently withdrawn because of
severe neuropathy. Treatment with a cyclophosphamide/
adriamycin/dexamethasone (CAD) regimen was followed
by a hematopoietic stem cell autograft for consolidation
three months after initiation of the VAD regimen. At the
age of 40 (i.e. after completion of the CAD regimen and
after the autograft), the patient complained of memory loss
and attention decline. A neuropsychological examination
was first performed 13 months after the onset of the
complaints and revealed moderately severe attention
and executive disorders (with a score of 17 out of 30 in
the Montreal Cognitive Assessment (MoCA) [15]). How-
ever, the patient also displayed mild language and epi-
sodic memory impairments. In a free and cued selective
reminding test (FCSRT) [16,17], free recall was most
strongly impaired (see Table 1). Brain MRI revealed a
few white matter lesions and two microbleeds. We made
a diagnosis of mild cognitive impairment due to chemo
brain.
Eighteen months after the hematopoietic stem cell
autograft, bone pain and an increase in the serum free
light lambda chain level (1250 mg/L in a Freelite® assay)
prompted the introduction of combination therapy with





Before lenalidomide treatment 20/48
During lenalidomide treatment 10/48
After lenalidomide withdrawal 31/48
1 year after lenalidomide withdrawal 27/48One month later, the patient’s cognitive impairment
progressively but significantly worsened and had a marked
impact on ADL. Two months after the initiation of
lenalidomide/ dexamethasone therapy, the patient was
admitted to our university medical center for cognitive
assessment. A neurological examination revealed psy-
chomotor impairment, lower limb sensory ataxia and the
abolition of reflexes. In a second cognitive assessment, the
patient was found to have a MoCA score of 20 out of 30
and an overall decrease in episodic memory performance
(in both free and cued recall) (see Table 1). We then
sought to establish the etiology of this cognitive impair-
ment. On the basis of the Freelite® test results, the patient
had a very good partial response. Serological tests for
paraneoplastic antibodies, HIV, syphilis, hepatitis, Lyme’s
disease, Whipple disease and autoimmune diseases were
negative. Assay results for metabolic disease (plasma and
urinary copper, plasma very long chain fatty acids and
blood amino acid, lactate and pyruvate levels) and thyroid
function were normal. The only finding was a low
thiamine level (64nmol/L, compared with a normative
value of >95nmol/L). No fragile X mutation was found.
Examination of the cerebrospinal fluid (CSF) confirmed
the absence of malignant cells and oligoclonal bands.
Proteinorachia and glycorachia values were normal. Cere-
brospinal fluid bacterial cultures, neurotropic virus cultures
and tuberculosis mycobacterium polymerase chain reaction
assays were all negative. The patient tested negative for
14.3.3 protein. Although the brain MRI results had not
changed since the previous scan, single photon emission
computed tomography (SPECT) with 99m Tc-HMPAO
revealed left temporal hypoperfusion (Figure 1). Electroen-
cephalography showed slow activity. The ophthalmological
examination was normal. An electromyogram revealed
chemotherapy-induced sensorimotor axonal neuropathy.
Nevertheless, the rapid cognitive decline was still unex-
plained on release of the patient from hospital.
One month later, the patient’s state worsened, with the
development of marked apathy, anorexia and somnolence.
A clinical examination revealed a sacral pressure ulcer.
Laboratory tests evidenced pancytopenia (platelet count:
46 ×109/L; neutrophil count: 0.2 ×109/L; hemoglobin level:
7.6g/dl) and an inflammatory syndrome (C-reactive protein:











Figure 1 Results from the first SPECT scan (during the course
of lenalidomide treatment). Note the left temporal hypoperfusion
in the transverse (top) and sagittal (bottom) slices.
Figure 2 Results from the second SPECT (after the cessation of
lenalidomide treatment). Note the normal perfusion in the
transverse (top) and sagittal (bottom) slices.
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the patient developed fever with diarrhea caused by
non-typhi Salmonella (prompting the initiation of antibiotic
treatment). Given the severe neutropenia and the infectious
syndrome, lenalidomide was withdrawn and replaced by
cyclophosphamide. The patient’s cognitive functions were
seen to have improved during hospitalization, with a Mini
Mental State Examination (MMSE) score [18] of 28 out of
30 one month after the withdrawal of lenalidomide. Three
months later, the MoCA score was 27 out of 30. Cognitive
function (and particularly episodic memory performance)
had improved (Table 1). One year later, the cognitive profile
had stabilized (with the persistence of mild attention
disorders) and the 99m Tc-HMPAO SPECT results were
normal (Figure 2).
Patient 2
The second patient was a 70 year-old male admitted to
our hospital for progressive cognitive decline. He had a
history of ISS stage I IgG kappa MM (in the absence of
chromosome 17 deletion or a 4;14 translocation) with onset
six years previously. He had initially been treated with
two VAD induction cycles and a subsequent hematopoietic
stem cell autograft and had shown a partial response. After
three treatment-free years, the patient presented with a
progression of MM. Combination therapy with bortezomib
and an anti-insulin-like growth factor-1 antibody was
introduced. These agents were withdrawn after 4 months
because of the occurrence of severe neuropathy and
were not replaced. Eighteen months later, combinationtherapy with lenalidomide, dexamethasone and an anti-
CS1 antibody was initiated following an increase in the
M component, with no signs of hyperviscosity syndrome.
After one month of treatment, the patient complained of
memory loss, apathy and word-finding difficulties, with
repercussions on ADL. An initial cognitive assessment
revealed a severe impairment in episodic memory (with
poor free and cued recall in the FCSRT, see Table 2),
whereas other cognitive functions (such as executive func-
tion and construction) were within the normal range. The
patient’s global cognitive efficiency was scored as 128 out
of 144 on the Mattis Dementia Rating Scale (DRS) [19] and
26 out of 30 in the MMSE. The neurological examination
was normal. Brain MRI revealed widespread white matter
lesions and overall atrophy. The patient was offered regular
clinical monitoring. Seven months later, the patient devel-
oped erythroderma and so lenalidomide was withdrawn.
The patient and his wife both reported an overall improve-
ment in cognitive function, with a decrease in apathy and
improved memory. The patient had recovered his inde-
pendence in ADL. A cognitive assessment was performed
six months after the withdrawal of lenalidomide treatment.
Although the patient’s global cognitive efficiency was stable
(128 out of 144 on the Mattis DRS and 27 out of 30 in the
MMSE), a slight improvement in performance in the
FCSRT was apparent (see Table 2). Given that episodic
memory was still the main dysfunction in our patient, we
made a diagnosis of amnesic mild cognitive impairment. In
an evaluation 12 months later, performance in the FCSRT
was still improved.









During lenalidomide treatment 6/48 29/48 1/16 10/16
6 months after lenalidomide withdrawal 12/48 35/48 4/16 12/16
12 months after lenalidomide withdrawal 11/48 37/48 3/16 13/16
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Here, we described two patients in whom cognitive im-
pairments developed or worsened significantly during
lenalidomide treatment. In both cases, the neuropsycho-
logical manifestations and the impact on ADL appeared
within one month of lenalidomide initiation. Both patients
presented with a severe impairment in episodic memory, i.e.
the ability to learn and retain new information. This
impairment was evidenced in both cases by poor perform-
ance in the FCSRT. Moreover, the patients showed also
evidence of a significant impairment in social and occupa-
tional functioning.
Lenalidomide is an immunomodulatory derivative of
thalidomide that is approved for the treatment of first
relapse in MM and is currently in clinical development
for other malignant hematologic indications. The drug has
anti-tumor, anti-angiogenesis and immunomodulatory
effects. The most frequently reported adverse event (AE) for
lenalidomide is immunosuppression (mainly neutropenia
and thrombocytopenia), although the drug is considered
as having a predictable safety profile and manageable
effects. Venous thromboembolism is the most frequent
non-hematologic AE [20]. In contrast to thalidomide,
lenalidomide is not associated with a significant level
of peripheral neurotoxicity. The incidence of grade 3
or 4 peripheral neuropathy reported in Phase III trials
is below 2% and lenalidomide does not appear to worsen
preexisting peripheral neuropathy [20,21]. A death in a
Phase III study of 176 lenalidomide-treated MM patients
was ascribed to leukoencephalopathy but no details were
provided [20]. However, we are not aware of any reports
of major cognitive impairments and ADL difficulties asso-
ciated with lenalidomide administration.
Several lines of evidence suggest that lenalidomide was
responsible for the cognitive impairment observed in our
two patients. Firstly, there was a temporal relationship
between the observed disorders and lenalidomide adminis-
tration. Even though Patient 1 complained of cognitive im-
pairment before starting lenalidomide, his episodic memory
clearly worsened after lenalidomide was administered.
This worsening was very acute and unexpected. Despite
wide-ranging investigations (MRI, lumbar puncture and
laboratory tests), no infectious, vascular, metabolic or
paraneoplastic etiologies were found. In the second case,
neither the patient nor his wife reported the presence of
cognitive difficulties prior to initiation of lenalidomide.The cognitive disorders occurred within one months of
the start of lenalidomide treatment. Secondly, we noticed
a significant improvement in episodic memory (a major
improvement for the first patient and a slight improve-
ment for the second) and independence in ADL after
lenalidomide withdrawal. This improvement in memory
performance was still present a year later in both cases.
Thirdly, the presence of left temporal hypoperfusion on
SPECT fits with the observed impairment in the FCSRT.
When lenalidomide was withdrawn, the SPECT results
normalized. These changes may indicate that lenalidomide
has a toxic effect on temporal structures. To the best of our
knowledge, this is the first report of brain hypoperfusion
associated with lenalidomide treatment.
Nevertheless, it is not possible to unequivocally state
that lenalidomide is directly neurotoxic. Indeed, the
Naranjo Adverse Drug Reaction Probability score was 6
out of 13 for Patient 1 and 5 out 13 for Patient 2, which
corresponds to a probable adverse drug reaction [22]. A
score above 9 corresponds to a definite adverse drug
reaction, which was not the case here – primarily because
(i) there are no previous conclusive reports on this reaction
and (ii) the drug was not detected in blood (or other fluids)
in concentrations known to be toxic. However, both
patients had several putative risk factors for chemo
brain, which may well explain their very poor cognitive
tolerance of lenalidomide. Both had already undergone a
cycle of chemotherapy before starting on lenalidomide
and Patient 1 had already complained of cognitive impair-
ment. The various drugs used to treat Patient 1’s MM
(bortezomib, vincristine, dexamethasone and especially
adriamycin [23,24]) could have been involved in chemo
brain. However, Patient 2 did not have any memory com-
plaints prior to lenalidomide initiation – despite having
already received several antineoplastic agents. Patient 2
was elderly; cognitive assessment after lenalidomide
withdrawal revealed the persistence of an episodic memory
impairment in the FCSRT, which is a predictive factor for
prodromal Alzheimer’s disease (AD) [25]. Moreover, MRI
showed overall atrophy of the brain (including the hippo-
campal regions) and many white matter lesions. Thus, a
diagnosis of prodromal AD could be considered in this
case. Cerebrospinal fluid analysis with AD biomarker assays
would have refined this diagnosis [26]. The presence of
cerebrovascular lesions can also increase the risk of cogni-
tive impairment. These observations suggest the existence
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suggested that age, lack of cognitive reserve, genetic risk
factors, comorbid conditions and other cancer-related
symptoms contribute to chemo brain [10]. Moreover,
the results of longitudinal studies have shown that 20%
to 30% of patients have cognitive deficits prior to the start
of treatment [5,27-29]. Some researchers have assessed
cognitive functions immediately after cancer diagnosis
and prior to starting chemotherapy (which is an especially
stressful period) and have suggested that cognitive deficits
may be stress-related [27]. The presence of the apolipo-
protein E ε4 (APOE E4) allele (which constitutes a strong
risk factor for AD) [30] has also been suggest as a risk
factor for chemo brain. A study found that E4 allele
carriers being treated for breast cancer or lymphoma with
chemotherapy tended to score less well in tests of visual
memory, spatial ability and psychomotor functioning
than survivors with other apolipoprotein alleles [10].
The potential mechanism of the interaction between
chemotherapy and APOE status remains unclear. We
did not perform APOE genotyping here because it is not
currently recommended in the diagnosis of AD or other
forms of dementia [31].
The putative mechanism by which lenalidomide may have
an impact on cognition is also unknown. Lenalidomide
has anti-angiogenic, anti-inflammatory and anti-neoplastic
effects in preclinical models [32]. An anti-angiogenic effect
might prohibit neurogenesis in hippocampal structures.
Furthermore, it is not known to what extent lenalidomide
can cross the blood–brain barrier (BBB) into the central
nervous system (CNS). There are two reports of the remis-
sion of CNS progressions of hematologic malignancies
(one diffuse large B cell lymphoma and one blastic mantle
cell lymphoma) after lenalidomide treatment [33,34]; this
suggests that lenalidomide may be able to cross a damaged
BBB. We suspect that lenalidomide crossed the BBN in
our two cases reports, albeit in the absence of a clearly
identified mechanism. As with chemo brain in general,
the mechanism of lenalidomide’s putative neurotoxicity
is not clear. Several mechanisms could be suspected:
direct neurotoxic effect of the drug, oxidative stress and
DNA damage, induced hormonal changes, immune
dysregulation, cytokine release, vascular injury and blood
clotting in small vessels and a genetic predisposition.
Conclusion
Here, we reported on the potential negative impact of
lenalidomide on episodic memory in two MM patients
undergoing chemotherapy. Although the symptoms were
reversible, they were severe enough to lead to a loss of
independence in ADL. The mechanism of these specific
cognitive deficits is unknown. Lenalidomide’s putative
neurotoxicity is probably exacerbated by risk factors (e.g.
previous mild cognitive impairment, prior chemotherapy,age, cerebrovascular lesions, etc.) and some patients may
be particularly vulnerable to the onset of cognitive impair-
ments and a subsequent loss of independence in ADL.
There is a need to further identify and characterize the
risks of cognitive impairment in patients being treated
with immunomodulators.
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